Another promising approach is the use of microRNA (miRNA) therapeutics, such as miR-192 and miR-215, which have been shown to downregulate TYMS expression and restore chemosensitivity in CRC cells (76, 77). This evidence concerns the gene TYMS and colorectal carcinoma.